Compare Heron Therapeutics Inc (HRTX) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Icl Group Ltd — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $61.47M), while Icl Group Ltd trades at $5.45 (market cap $6.94B). The key difference: Icl Group Ltd is far larger — about 112.9× Heron Therapeutics Inc's market cap, and Icl Group Ltd pays a 3.86% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | ICL | |
|---|---|---|
Market Cap | $61.47M | $6.94B |
Sector | Health | Basic Materials |
52-Week High | $1.49 | $6.84 |
52-Week Low | $0.32 | $4.80 |
Enterprise Value | $168.21M | $9.58B |
Dividend Yield | — | 3.86% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
